{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:42:26Z","timestamp":1793882546651,"version":"4.7.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["0F04022"],"award-info":[{"award-number":["0F04022"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202002030135"],"award-info":[{"award-number":["202002030135"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102010082"],"award-info":[{"award-number":["202102010082"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102020393"],"award-info":[{"award-number":["202102020393"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873920"],"award-info":[{"award-number":["81873920"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903071"],"award-info":[{"award-number":["81903071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001929"],"award-info":[{"award-number":["82001929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172043"],"award-info":[{"award-number":["82172043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.biopha.2023.114254","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:11:39Z","timestamp":1674137499000},"page":"114254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma"],"prefix":"10.1016","volume":"159","author":[{"given":"Lulu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liteng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-010X","authenticated-orcid":false,"given":"Kangshun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.114254_bib2","doi-asserted-by":"crossref","unstructured":"Vogel A., Cervantes A., Chau I., Daniele B., Llovet J.M., Meyer T., et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol 2018;29(Suppl 4):v238-v255, doi:10.1093\/annonc\/mdy308.","DOI":"10.1093\/annonc\/mdy308"},{"issue":"10088","key":"10.1016\/j.biopha.2023.114254_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancel"},{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancel Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114254_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancel Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114254_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114254_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2023.114254_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.biopha.2023.114254_bib9","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2023.114254_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN-\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.114254_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res"},{"key":"10.1016\/j.biopha.2023.114254_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"14","key":"10.1016\/j.biopha.2023.114254_bib13","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-18-2840","article-title":"Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma","volume":"25","author":"Wu","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7693","key":"10.1016\/j.biopha.2023.114254_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF-\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.biopha.2023.114254_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF-\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib16","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114254_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2045-3701-4-22","article-title":"Mesenchymal stem cells contribute to the chemoresistance of hepatocellular carcinoma cells in inflammatory environment by inducing autophagy","volume":"4","author":"Han","year":"2014","journal-title":"Cell Biosci."},{"issue":"22","key":"10.1016\/j.biopha.2023.114254_bib18","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/hmg\/ddg321","article-title":"NSDHL, an enzyme involved in cholesterol biosynthesis, traffics through the Golgi and accumulates on ER membranes and on the surface of lipid droplets","volume":"12","author":"Caldas","year":"2003","journal-title":"Hum. Mol. Genet"},{"issue":"2","key":"10.1016\/j.biopha.2023.114254_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-021-06213-8","article-title":"NSDHL promotes triple-negative breast cancer metastasis through the TGF-\u03b2 signaling pathway and cholesterol biosynthesis","volume":"187","author":"Chen","year":"2021","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"10.1016\/j.biopha.2023.114254_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","article-title":"Cholesterol pathway inhibition induces TGF-\u03b2 signaling to promote basal differentiation in pancreatic cancer","volume":"38","author":"Gabitova-Cornell","year":"2020","journal-title":"Cancer Cell"},{"issue":"10064","key":"10.1016\/j.biopha.2023.114254_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancel"},{"key":"10.1016\/j.biopha.2023.114254_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001435","article-title":"Regorafenib combined with PD-1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma","volume":"8","author":"Shigeta","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.114254_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: Looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J. Hepatol."},{"issue":"16","key":"10.1016\/j.biopha.2023.114254_bib25","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2023.114254_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114254_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","article-title":"Expanding roles for SREBP in metabolism","volume":"16","author":"Shao","year":"2012","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.biopha.2023.114254_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF-\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114254_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","article-title":"An early history of T cell-mediated cytotoxicity","volume":"18","author":"Golstein","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2023.114254_bib31","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill cancer cells","volume":"21","author":"Martinez-Lostao","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.biopha.2023.114254_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGF-\u03b2, Nat Rev","volume":"10","author":"Flavell","year":"2010","journal-title":"Rev. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114254_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2023.114254_bib34","first-page":"161","article-title":"IFN signaling and ICB resistance: time is on tumor's side, trends","volume":"3","author":"Lopez-Soto","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114254_bib35","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.114254_bib36","doi-asserted-by":"crossref","first-page":"a021873","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-\u03b2 and the TGF-\u03b2 family: context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114254_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2005.12.022","article-title":"Protein sensors for membrane sterols","volume":"124","author":"Goldstein","year":"2006","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2023.114254_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cmet.2016.11.009","article-title":"SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism","volume":"25","author":"Oishi","year":"2017","journal-title":"Cell Metab."},{"issue":"13","key":"10.1016\/j.biopha.2023.114254_bib39","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1158\/0008-5472.CAN-20-3944","article-title":"Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1\/SREBP1 Signaling","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2023.114254_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-018-0158-8","article-title":"SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1\/2","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.biopha.2023.114254_bib41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/2211-5463.13137","article-title":"SREBP1\/FASN\/cholesterol axis facilitates radioresistance in colorectal cancer","volume":"11","author":"Jin","year":"2021","journal-title":"Febs Open Bio"},{"issue":"6","key":"10.1016\/j.biopha.2023.114254_bib42","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:50:49Z","timestamp":1773388249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"alternative-id":["S0753332223000422"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114254","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114254"}}